
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
As planned, a total of 5 cohorts were enrolled at 3 clinics in the United States. Several study data sets are expected during Q3 2025: these will include safety parameters, changes in hematologic parameters, in vitro evaluation of the inflammatory response in peripheral blood mononuclear cells isolated from study participants, and multiple biomarkers of activity.
'We thank our Investigators and participants for the rapid completion of dosing,' said James Rolke, Chief Executive Officer of Revelation. 'We are looking forward to sharing the study data shortly, and engaging the FDA to discuss future clinical development and approval pathways later this year.'
About Gemini
Gemini is an intravenously administered, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD ®) that reduces the damage associated with inflammation by reprograming the innate immune system to respond to stress (trauma, infection, etc.) in an attenuated manner.
Gemini is being developed for multiple indications including as a pretreatment to prevent or reduce the severity and duration of acute kidney injury (GEMINI-AKI program), and as pretreatment to prevent or reduce the severity and duration of post-surgical infection (GEMINI-PSI program), or infection post severe burn (GEMINI-PBI). Gemini may also be a treatment to stop or slow the progression of chronic kidney disease (GEMINI-CKD program).
Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications. Revelation previously announced positive Phase 1 clinical data for intravenous treatment with Gemini: the primary safety endpoint was met in the Phase 1 study, and results demonstrated statistically significant pharmacodynamic activity, as observed through expected changes in multiple biomarkers including upregulation of IL-10.
About CKD
Chronic kidney disease is a pervasive problem in the United States and world-wide. CKD is caused by chronic inflammation and can be initiated and propagated in several ways. One prevalent condition is the high blood sugar levels associated with diabetes (either Type 1 or Type 2): high blood sugar is toxic to kidney cells – it creates stress, which imitates the inflammatory process, leading to the demise of these cells with subsequent fibrosis, ultimately resulting in continuous loss of kidney function over time.
High arterial blood pressure is another source of stress that initiates the inflammatory process that results in CKD. Other risk factors include heart disease, obesity, family history of CKD, or advanced age. Progression of chronic kidney damage often leads to end stage renal disease with the need for renal replacement therapy (dialysis or transplantation), resulting in significant morbidity and mortality for affected patients. Kidney disease is a leading cause of death in the United States.
About AKI
AKI, also known as acute renal failure, is a rapid loss of kidney function. AKI causes a build-up of waste products in the blood, making it more difficult for kidneys to maintain the correct balance of fluid in the body. AKI can also have a significant impact on other organs, such as the brain, the heart, and the lungs.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, for post-severe burn infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.
For more information on Revelation, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Intuitive Machines (LUNR) Soars 18.5% on Rosy Prospects from US, China Space Race
We recently published . Intuitive Machines, Inc. (NASDAQ:LUNR) is one of the biggest performers on Wednesday. Intuitive Machines soared by 18.53 percent on Wednesday to end at $13.37 apiece as investors took path from an investment firm's bullish coverage for the company. In a market note, investment bank Craig-Hallum gave a 'buy' recommendation on shares of Intuitive Machines, Inc. (NASDAQ:LUNR) with a price target of $17. The new figure marked a 27-percent upside from its latest closing price. According to Craig-Hallum, Intuitive Machines, Inc. (NASDAQ:LUNR) stands to benefit from the aggressive space race between the United States and China, both of which are targeting to again land humans on the moon by 2030. In other news, Intuitive Machines, Inc.'s (NASDAQ:LUNR) inked a deal with Space Forge for the integration of the latter's semiconductors into its orbital return platform, Zephyr, to support its Earth reentry program. The program is backed by the Texas Space Commission's Space Exploration and Research Fund. Intuitive Machines, Inc. (NASDAQ:LUNR) is scheduled to release the results of its second quarter earnings performance before market open on August 7. While we acknowledge the potential of LUNR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Yahoo
22 minutes ago
- Yahoo
RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025
ALISO VIEJO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 633359. The call will also be broadcast live in listen-only mode via a link on the company's investor relations website at An archived recording of the call will be available through the same link shortly after its completion. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the 'LAL'), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at Company Contact:Shelley B. ThunenChief Financial Officersthunen@ Investor Relations Contact:Oliver MoravcevicVP, Investor Relationsomoravcevic@
Yahoo
22 minutes ago
- Yahoo
Kennel Connection Deepens Technical Strategy with Paul D'Arrigo Appointment
MOORPARK, Calif., July 24, 2025--(BUSINESS WIRE)--Kennel Connection, a leader in pet care management software and a 100GROUP company, has officially appointed Paul D'Arrigo as Lead Technical Advisor to the CEO — a key transition that strengthens the company's leadership as it continues to grow and innovate. Paul has been a trusted advisor to Kennel Connection for the past seven years, offering his expertise in various fractional consulting roles. With more than 20 years of experience in software and operational strategy, Paul's extensive knowledge has played a pivotal role in advancing the company's technical infrastructure, SaaS capabilities, and overall platform performance, including key improvements to backend systems and SEO. In his new full-time role, Paul will take on a more hands-on position focused on driving technical innovation and operational efficiency. His responsibilities will include strengthening backend architecture, optimizing SaaS performance, onboarding development staff, and integrating smart technology to improve platform efficiency. Paul's deep understanding of Kennel Connection's needs, along with his collaborative approach, will allow him to collaborate on strategic initiatives across departments, playing a key role in shaping product direction and scaling the platform. "I'm incredibly excited to step into this new role and help accelerate the momentum at Kennel Connection," said Paul D'Arrigo, newly appointed Lead Technical Advisor to the CEO. "Having worked alongside the team for years, I've seen firsthand the passion behind the product and the potential for growth. I'm looking forward to deepening our technical capabilities and delivering smart, scalable solutions that make a real difference for pet care businesses." "Paul's ability to bring teams together and focus on operational growth has been instrumental to Kennel Connection's evolution," said Jeff Brodsly, Owner and CEO of Kennel Connection and 100GROUP. "We're thrilled to officially welcome him into this new role and look forward to the innovation he'll help drive as we continue as a market leader in pet care software." Kennel Connection looks forward to advancing its critical initiatives under Paul's leadership. His expertise will be instrumental in driving innovation and delivering industry-leading solutions that empower pet care businesses. About Kennel Connection Kennel Connection is a leading provider of innovative software solutions for pet care businesses, offering a comprehensive suite of management tools designed to streamline operations and enhance customer experience. With a focus on empowering pet care professionals, Kennel Connection's feature-rich platform encompasses reservation management, client communication, billing, and reporting, alongside innovative features such as Text-To-Pay, digital contracts, advanced online booking, and integrated credit card processing aimed at driving efficiency and organization in day-to-day operations. Kennel Connection leverages cutting-edge technology to deliver tailored solutions that cater to the unique needs of pet boarding facilities, grooming salons, and dog daycare centers. For more information, please visit View source version on Contacts erin@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data